Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell symbols : Sngx save search
HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
Published: 2023-08-10 (Crawled : 13:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 0.02%
H: 0.37%
C: -2.78%
t-cell treatment trial
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-05-11 (Crawled : 12:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 3.5%
H: 0.58%
C: -8.88%
fda t-cell review treatment meeting study
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-05-04 (Crawled : 12:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 150.7%
H: 17.98%
C: -35.96%
t-cell positive treatment results study
Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-04-24 (Crawled : 12:00) - prnewswire.com
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 10.53%
H: 0.0%
C: -8.33%
fda t-cell review treatment meeting study
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-04-03 (Crawled : 19:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: -3.55%
H: 11.45%
C: 6.32%
fda drug t-cell treatment meeting application
Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-03-09 (Crawled : 13:00) - prnewswire.com
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: -2.09%
H: 14.23%
C: 8.9%
treatment fda drug meeting t-cell application
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-02-14 (Crawled : 13:00) - prnewswire.com
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: -31.38%
H: 19.35%
C: 19.35%
treatment fda drug t-cell application
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
Published: 2022-12-15 (Crawled : 13:00) - prnewswire.com
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 7.78%
H: 11.68%
C: 5.29%
treatment fda drug t-cell application submission
U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2022-09-06 (Crawled : 12:00) - prnewswire.com
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 1.38%
H: 1.38%
C: -5.47%
treatment awards drug grant t-cell food study
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Published: 2022-07-27 (Crawled : 12:00) - prnewswire.com
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 1.91%
H: 11.1%
C: -2.57%
treatment fda t-cell agreement study
HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology
Published: 2022-07-20 (Crawled : 16:00) - prnewswire.com
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 2.32%
H: 23.23%
C: 8.54%
treatment t-cell study
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
Published: 2021-09-09 (Crawled : 12:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 12.38%
H: 4.24%
C: -1.69%
treatment fda drug t-cell granted grant designation
Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
Published: 2021-02-01 (Crawled : 14:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 1.42%
H: 3.69%
C: 0.51%
patent t-cell
Soligenix Announces Investor Webcast Event: U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2021-01-19 (Crawled : 18:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 0.98%
H: 21.19%
C: 15.65%
t-cell treatment commercialization
Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2021-01-07 (Crawled : 19:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 9.92%
H: 5.56%
C: -0.69%
partnership distribution t-cell treatment
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.